This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit þ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well tolerated up to 400 mg/day imatinib. Of 21 patients treated at this dose, 13 (62%) achieved complete response (CR), 7 (33%) were non-responders and one died during induction. The CR rate was 80% in patients with standard-risk karyotype versus 33% in patients with adverse karyotype. The CR rate for primary non-responders was 6/14 (43%) versus 7/7 (100%) for relapsed patients. AML blasts from peripheral blood were assayed for phosphorylated Akt (pAkt) and phosphorylated ERK (pERK) by flow cytometry before to and after imatinib dosing. Of eight patients achieving CR with reinduction, seven demonstrated marked (X60%) pAkt inhibition with imatinib therapy. In contrast, all the six non-responders to reinduction demonstrated o60% pAkt inhibition (P ¼ 0.005). There was no correlation between pERK inhibition and response to therapy. These results indicate that lack of pAkt inhibition in vivo is associated with resistance to reinduction therapy using this regimen. Further studies using agents that are able to inhibit Akt more effectively are warranted. Leukemia (2011) 25, 945-952;
Introduction
Standard frontline chemotherapy for acute myeloid leukemia (AML), using cytarabine plus an anthracycline ('3 þ 7' regimen), produces complete response (CR) rates of 70% in patients under age 60 years and 50-55% in patients aged X60 years. [1] [2] [3] [4] [5] For patients who do not achieve CR, reinduction chemotherapy with a second-line regimen is commonly used. 6, 7 We recently reported our results using one such reinduction regimen, a combination of mitoxantrone, etoposide and modified highdose cytarabine (NOVE-HiDAC), in primary induction failures. 6 The CR rate with this regimen was 50%; however, the relapse rate was B80% with median CR duration of only 9 months, 6 indicating that this is a poor-risk group. For patients who achieve CR and subsequently relapse, similar reinduction regimens have been used. [7] [8] [9] For patients with CR-1 duration of up to 1 year, CR-2 rates are in the 30-40% range and somewhat higher for patients with CR duration of 1-2 years. 8 However, second remissions are rarely durable, unless allogeneic stem cell transplantation (alloSCT) is performed; median overall survivals (OSs) of o6 months have been reported. [8] [9] [10] There is therefore an urgent need for improved treatments for these patients to achieve more frequent and durable remissions.
C-kit (stem cell factor (SCF) receptor) is a tyrosine kinase receptor expressed in 65-90% of AML cases. 11 Binding of c-kit results in activation of several intracellular pathways, including JAK-STAT, PI 3-kinase/Akt and ERK MAP kinase, which promote cell growth and differentiation. 12 Stimulation of c-kit in AML cells in vitro induces proliferation and inhibits apoptosis. 11 Because of this, there is an interest in exploring the use of c-kit inhibitors in AML. Imatinib mesylate has been shown to inhibit c-kit activation and c-kit-dependent proliferation, and also reverses the antiapoptotic effects of c-kit activation. 13 There have been several published reports of antileukemic activity using imatinib as a single agent in patients with c-kit-positive AML. A German Study treated 12 patients with c-kit-positive AML, most with relapsed/refractory disease, using imatinib 600 mg daily.
14 There were two partial and two CRs; the median response duration was 108 days. Another study reported 5/21 responses in c-kit-positive AML; inhibition of c-kit tyrosine phosphorylation in AML blasts was demonstrated. 15 In addition to the single-agent activity in AML, there is evidence that c-kit deregulation and overexpression may be a factor in resistance to conventional chemotherapeutic agents in AMLFcorrelations have been found between high c-kit expression and low CR rates and relapse-free survival (RFS) using conventional chemotherapy in AML. 16 Inhibition of c-kit activation may potentially reverse antiapoptotic intracellular mechanisms, particularly via inhibition of phosphorylation of downstream intermediates such as PI 3-kinase/Akt, thereby circumventing chemotherapy drug resistance. 17, 18 Based on these considerations, we designed a phase I-II clinical trial combining imatinib with reinduction chemotherapy for patients with primary induction failure or relapse following 3 þ 7 therapy for c-kit-positive AML. The primary objectives were to determine the maximum tolerated dose of imatinib that could be used in this setting, to evaluate the toxicity of the combination and to determine response rate at the maximum tolerated dose. Patients received a prechemotherapy phase with imatinib to inhibit c-kit; imatinib was then continued during chemotherapy to maintain this effect. The study design permitted correlative studies to evaluate the effects of imatinib on downstream mediators in the c-kit pathway in vivo.
Materials and methods

Eligibility criteria
The study was open from October 2004 to December 2008. Patients with any subtype of AML except acute promyelocytic leukemia were eligible. All patients had received previous induction therapy with cytarabine 100-200 mg/m 2 per day Â 7 days plus daunorubicin 60 mg/m 2 daily Â 3 (3 þ 7), with either one of the following: persistent leukemia after one cycle or CR with relapse within 2 years. Patients under age 60 years achieving CR with 3 þ 7 had received two consolidation cycles, each cycle consisting of cytarabine 3 g/m 2 q12 h Â 6 doses plus daunorubicin 45 mg/m 2 daily Â 2. Patients aged X60 years had received two consolidation cycles, consisting of 3 þ 7, followed by mitoxantrone and etoposide (NOVE). No patients had undergone alloSCT before study enrollment.
The diagnosis of AML was made on the basis of morphology and immunophenotyping. Cytogenetic-risk groups were defined as per Grimwade et al. 2 Patients were required to have at least 10% marrow blasts or biopsy-confirmed extramedullary disease. AML blasts were required to have at least 30% positivity for CD117 (c-kit receptor) by flow cytometry. Initially, patients aged 18-75 years were eligible; after the phase I portion was completed, the upper age limit was reduced to 65 years because of excessive toxicity seen in older patients (see Results). Other eligibility criteria included Eastern Cooperative Oncology Group performance status 0-2, left ventricular ejection fraction X 50% by multiple gated acquisition scan (MUGA) or echocardiogram, serum creatinine p200 mmol/l, serum bilirubin p1.5 Â upper limit of normal and serum AST/ALT p2 Â upper limit of normal. Patients with active central nervous system leukemia or uncontrolled infections were not eligible. All patients were required to sign an informed consent prior to participating. The study protocol and consent form were approved by the local institutional review board. Imatinib was provided by Novartis Canada Inc. Cytogenetic-risk groups were classified according to MRC criteria as previously described. 2 
Treatment regimen
The induction phase consisted of imatinib dose once daily on days 1-10, mitoxantrone 10 mg/m 2 intravenous (IV) daily Â 5 on days 4-8, etoposide 100 mg/m 2 IV daily Â 5 on days 4-8 and cytarabine 1.5 g/m 2 IV (1.0 g/m 2 for patients X age 60 years) over 3 h, repeated every 12 h Â 4 doses on days 9-10. On days 4-8, chemotherapy was started approximately 2-4 h after each imatinib dose. During the phase I portion of the study, imatinib was escalated over three dose levels in successive cohorts of patients: 200, 300 and 400 mg daily; six patients were treated at each dose level.
Toxicity evaluation
All patients who started chemotherapy on day 4 were considered evaluable for toxicity. Non-hematological toxicity was graded according to the National Cancer Institute Common Toxicity Criteria. Any grade III-IV toxicity was considered dose limiting, with the exception of grade III nausea, vomiting or mucositis, which were only considered a dose-limiting toxicity (DLT) if lasting more than 7 days, and grade III electrolyte abnormalities. Because the induction therapy was expected to produce marrow aplasia for 28-30 days, hematological recovery times (platelets 420 Â 10 9 /l independently of transfusions or absolute neutrophil count (ANC) X0.5 Â 10 9 /l) greater than 40 days from the first day of chemotherapy were considered dose limiting. Neutropenic infections were not considered dose limiting, unless related to prolonged hematological recovery or other severe toxicity.
Because of the intensity and anticipated toxicity of the chemotherapy regimen, up to two DLTs were permitted at each dose level. If p2 DLTs were seen, subsequent patients were treated at the next higher dose level. If 42 DLTs were seen, this was considered dose limiting, and the next lowest dose would be considered the recommended dose.
Evaluation of response
Bone marrow aspirate±biopsy was performed on days 28-30 or at hematological recovery. Responses were defined as follows: (1) Complete remission (CR): blasts (o5%) in a normocellular bone marrow, absolute neutrophil count 41.0 Â 10 9 /l and platelets 4100 Â 10 9 /l, and no extramedullary disease. (2) Morphological leukemia-free state: blasts (o5%) in bone marrow and no extramedullary disease, but incomplete count recovery (absolute neutrophil count o1.0 Â 10 9 /l and/or platelets o100 Â 10 9 /l). (3) No response (NR): not meeting the criteria for CR or morphologic leukemia-free state. (4) Induction death: death from any cause during the postinduction phase before hematological recovery.
Postremission therapy
Patients achieving CR, and still meeting all other eligibility criteria with respect to organ function, were permitted to receive up to two cycles of consolidation therapy on study. Each consolidation cycle consisted of imatinib dose of 200-400 mg daily on days 1-8, cytarabine 3 g/m 2 (1.5 g/m 2 for patients aged X60 years) q12 h Â 6 doses total (2 doses each on days 4, 6 and 8) and mitoxantrone 12 mg/m 2 daily on days 4 and 5. Following recovery from consolidation no. 2, patients were started on maintenance therapy with imatinib at a fixed dose of 600 mg daily for up to 1 year or until disease recurrence. Patients were permitted to come off-study at any time following achievement of CR to undergo alloSCT.
Supportive care measures
All inductions were administered on an in-patient leukemia unit at Princess Margaret Hospital. Consolidation therapy was administered on either an in-patient or outpatient basis. During induction, all patients received allopurinol 300 mg daily on days 1-10 plus IV fluids as tumor lysis prophylaxis. Granisetron 1 mg IV daily was given on chemotherapy treatment days as antiemetic prophylaxis; additional antiemetics were given as required. Celecoxib was given on days 9-10 during induction, and indomethacin on days 4-8 during consolidation, to prevent cytarabine-induced fevers. Prednisolone 1% eye drops were used to prevent cytarabine-related conjunctivitis. Antifungal prophylaxis with fluconazole 400 mg daily was given, starting at the day following the completion of imatinib treatment during both induction and consolidation. Patients receiving outpatient consolidation also received ciprofloxacin plus amoxicillin as antibacterial prophylaxis. Febrile neutropenia was treated with IV broad-spectrum antibiotics according to institutional policy. Hematopoietic growth factors were not routinely used during induction or consolidation, but filgrastim was permitted during consolidation for severe infections at the physician's discretion.
Correlative studies Pharmacodynamic assays. Blood samples were drawn on days 1 and 4, immediately before, and at 1 and 2 h after imatinib administration on each day. Day 4 samples were drawn before chemotherapy administration. Flow cytometry was used to measure the pharmacodynamic effects of imatinib treatment on signaling via the c-kit receptor in peripheral blood blast cells. This involved acute ex vivo activation by the c-kit ligand SCF, as previously reported, 19 ,20 using a whole-blood assay procedure developed by Chow et al. 21 Based on preliminary dose/response and kinetic studies, a final SCF concentration of 50 ng/ml was added to 100 ml aliquots of undiluted whole blood at 371C, followed by fixation after 5 min with the addition of 10% methanol-free formaldehyde to give a final concentration of 4%. After 10 min, Triton X-100 was added to give a final concentration of 0.1% for 30 min to lyse red blood cells. Samples were then either held in a 20% glycerol/10% fetal calf serum freezing mixture at À701C or processed immediately for flow cytometry. Samples were washed, treated with 50% methanol as previously described 21 and then resuspended at 10 6 cells in 50 ml. Cells were dual stained for phosphorylated ERK (pERK) using an Alexa-488-conjugated mouse monoclonal antibody and phosphorylated Akt (pAkt) using an Alexa-647-conjugated rabbit monoclonal antibody (both from Cell Signaling Technology, Danvers, MA, USA), which measures the serine 473 phosphorylation site of Akt. Based on the analysis of surface immunophenotypic markers, blast cells were labeled by the additional use of PC7-conjugated anti-CD34, -CD45 or -CD117. Samples were then washed, resuspended at 1 Â 10 6 /ml and analyzed using an FC500 flow cytometer equipped with blue and red lasers (Beckman-Coulter, Mississauga, Canada). Blast cells were identified using the combination of orthogonal light scatter and surface markers, and a minimum of 20 000 events collected per sample. The mean fluorescence intensities for pERK and pAkt were measured, and results for each of the six blood samples expressed as fold increase in intensity, following SCF stimulation, relative to an unstimulated control sample. The percent residual expression of each was defined as the activity of the day 4 at 2 h after imatinib sample divided by the activity of the day 0 before imatinib sample Â 100%.
Molecular studies C-kit assay. RNA extracted from bone marrow or peripheral blood was transcribed into complementary DNA and then amplified by using primers specific for exons 8 and 17 of the kit gene. PCR products were then purified and sequenced using a fluorescent dideoxy sequencing method 22 and then compared with the NCBI reference sequence (X06182.1). The lower limit of mutation detection is 10-15%. FLT3 mutation assays. RNA extracted from bone marrow or peripheral blood was transcribed into complementary DNA, then amplified using primers specific for the FLT3 gene. The FLT3-ITD (internal tandem duplication) mutation detection assay was done using fluorescently labeled PCR primers, followed by fragment analysis. 23 The sensitivity of this assay is 5%. The FLT3-TKD, D835 point mutation was assessed by reverse transcriptase PCR followed by an EcoRV restriction enzyme digest.
Statistical analysis
Descriptive statistics were reported as median and range for continuous variables, and frequencies and proportions for categorical variables. Fisher's exact test was used to compare proportions. Wilcoxon rank-sum test was used to compare continuous variables. OS was defined as the time from day 1 of induction until death from any cause or last follow-up. RFS for complete responders was defined as the time from documentation of CR until relapse or death from any cause or last followup. OS and RFS were calculated using the Kaplan-Meier method. Differences between survival curves were analyzed by log-rank test. Results were expressed with 95% confidence intervals. Two-sided tests were applied. Results were considered significant if P-value was p0.05. All the analyses were performed with SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
Baseline patient data are shown in Table 1 . A total of 14 patients were 460 years of age and 3 were 465 years of age. Antecedent hematological disorders included myelodysplastic syndrome (four patients), chronic myelomonocytic leukemia and polycythemia rubra vera (one patient each).
Toxicity data
The major induction toxicities at each dose level are summarized in Table 2 . At 200-mg imatinib dose, there were two DLTsFone transient grade III transaminitis and one prolonged neutrophil recovery (44 days). At 300-mg dose, there was one DLT consisting of grade III typhlitis and induction death (due to sepsis) in a 68-year-old patient. At 400-mg dose, there were 2/6 DLTs in the phase I portion consisting of one gastrointestinal hemorrhage, resulting in death in a 70-year-old patient, and one grade III typhlitis. During consolidation therapy, there were 0/3 and 0/2 DLTs at 200-and 300-mg doses, respectively, but 3/4 patients treated at 400-mg dose experienced delayed hematological recovery. As a result, the recommended phase II imatinib dose was determined to be 400 mg daily during induction and 300 mg daily during consolidation. In addition, because two patients over age 65 years died during induction during the phase I portion, it was decided to limit the phase II portion to patients p65 years of age.
During the phase II portion, there were 3/15 additional DLTs during inductionFtwo hematological (neutrophil recovery times of 53 and 54 days, respectively) and one grade IV atrial fibrillation with hypotension requiring intensive care. There were 7/15 additional cases of grade III mucositis during the phase II portion; all were of o7 days duration. There were no DLTs during consolidation during the phase II portion. A total of six patients proceeded to maintenance therapy with imatinibFthere were no major toxicities noted during this phase and no dose reductions were required.
Response data
Of the 33 patients treated at all doses, 20 (61%) achieved CR with induction. The induction responses at the phase II (400 mg) imatinib dose are summarized in Table 3 . At this dose, patients with poor-risk cytogenetics had a trend toward a lower CR rate, as compared with those with standard-risk karyotype (80 versus 33%, P ¼ 0.07). Of the seven relapsed patients, one had favorable, five standard and one adverse-risk cytogenetics. Of the 14 primary induction failures, 5 had standard and 8 adverserisk cytogenetics; the remaining 1 was inevaluable. Relapsed patients had a significantly higher CR rate, as compared with those with primary induction failure (100 versus 43%, P ¼ 0.02).
Other features such as age, antecedent hematological disorder or WBC at the start of treatment did not predict for response (data not shown).
Of the 20 patients achieving CR on study, 14 relapsed, with a median RFS of 6.8 months (95% confidence interval: 4.0-16.8 months). The RFS was not significantly different, comparing the patients who received 400-mg imatinib dose during induction with those who received 200 or 300 mg. Of the patients who achieved CR, eight subsequently proceeded to alloSCT; one additional patient underwent alloSCT with residual leukemia in the marrow.
Of the 33 patients on study, 25 have died (15/21 at 400-mg imatinib dose). Causes of death included induction-related toxicities (2 patients), leukemia-related complications (19 patients) and alloSCT-related complications (4 patients). The OS is shown in Figure 1 . The median OS for the entire group was 8.3 months (95% confidence interval: 6.2-15.2 months), and the 1-and 2-year OS were 39 and 17%, respectively. There was no significant difference in the OS, comparing the patients who received 400-mg imatinib dose during induction with those who received 200 or 300 mg (P ¼ 0.50). Of the eight patients alive, seven are in continuous CR at a median follow-up of 18 months (range 10-51 months); five of these have undergone alloSCT.
Correlative studies
A total of 14 patients treated at 400-mg imatinib dose during induction had ERK and Akt studies performed. Light scatter and surface immunofluorescence staining were well preserved using the flow cytometry procedure, allowing the detection of leukemic blast cells at frequencies of o1% of total nucleated cells. The effects of imatinib therapy on both pERK and pAkt activity in AML blasts ex vivo were variable, with some patients demonstrating a marked degree of inhibition by day 4 after imatinib administration and others showing little or no inhibition. Figures 2 and 3 show an example of a patient demonstrating marked in vivo inhibition of both ERK and Akt with imatinib in vivo, whereas Figure 3 shows a patient whose blasts demonstrated a lack of inhibition.
Of these 14 patients, 8 achieved CR with this reinduction regimen, whereas 6 had persistent leukemia (NR). Figure 4 shows the distribution of percent residual pAkt and pERK expression in the CR and NR groups, respectively. Patients who achieved CR demonstrated a significantly lower mean percent residual pAkt expression at day 4 at 2 h after imatinib administration, as compared with the group not achieving CR Figure 1 OS of all patients treated on study (n ¼ 33).
Imatinib plus chemotherapy for AML JM Brandwein et al (47.6 ± 13.9 versus 84.8 ± 21.9%, P ¼ 0.007). In contrast, there was no significant difference in the percent residual pERK expression after imatinib administration between the CR versus NR groups (64.8±23.2 versus 68.7±23.8%, P ¼ 1.0). Using a variety of cutoff values, it was determined that a level of 60% residual pAkt expression after imatinib administration provided the best discrimination between the CR versus NR groups. Results using this cutoff are shown in Table 4 . Patients demonstrating o60% residual pAkt activity after imatinib administration were significantly more likely to achieve CR, as compared with those with greater than 60% residual activity (P ¼ 0.005). In contrast, there was no significant correlation between percent residual pERK activity and response to therapy.
Of five patients with adverse-risk cytogenetics analyzed, four demonstrated resistance to Akt inhibition with imatinib (460% residual activity); the only patient showing sensitivity was also the only patient in this subset that achieved CR. In contrast, 5/9 patients with standard-risk cytogenetics showed sensitivity to Akt inhibition with imatinib. The correlation between Akt inhibition and cytogenetic-risk group was not, however, statistically significant (P ¼ 0.37). There was no correlation between pERK inhibition and cytogenetic-risk group (P ¼ 0.55).
There was a significant correlation between the degree of both pERK (P ¼ 0.009) and pAKT (P ¼ 0.001) inhibition by imatinib and the degree of stimulation of each at time 0 by SCF. When comparing the degree of SCF stimulation with response to treatment, there was a trend toward a greater degree of pAKT stimulation at time 0 in the CR patients, but this did not reach statistical significance (P ¼ 0.17 using Wilcoxon rank-sum test).
C-kit mutation assays were performed on bone marrow samples from 20/21 patients treated at 400-mg imatinib dose. No c-kit mutations were detected in any samples. Of 10 patients with standard-risk karyotype treated at 400-mg dose, one had an FLT3-ITD mutation and none had an FLT3-TKD mutation; none of the patients with favorable or adverse-risk karyotype were tested for FLT3 mutations.
Discussion
The study demonstrates the feasibility of combining imatinib with this three-drug reinduction regimen in AML. Although there were significant toxicities seen, these were not greater than what would generally be expected with the chemotherapy regimen alone. In particular, there was no evidence that hepatic toxicity or myelosuppression were increased. Mucositis was common, as would be expected with this intensive chemotherapy protocol, and appeared to be somewhat more severe at 400-mg dose, with more frequent grade III toxicity, but was within acceptable limits and in only one case met the preset criteria for DLT. However, the regimen did appear to be more toxic for older patients, particularly those over age 65 years.
The CR rate in primary induction failures (43%) was not higher than the 50% CR rate previously been reported using this chemotherapy regimen alone in primary induction failures. 6 The CR rate in relapsed patients did appear to be higher (7/7, 100%) than that what would normally be expected in such patients; [8] [9] [10] however, the numbers are small and this would have to be confirmed in a much larger study. Furthermore, the primary induction failure group had a higher proportion of patients with adverse cytogenetics, which could account for the difference. Further subgroup analysis is also limited by small numbers. However, the CR rate in patients with adverse-risk karyotype (33%) did also not appear to be substantially different than previously reported CR rates in such patients using this regimen. 6 The 80% CR rate in patients with intermediaterisk karyotype compares favorably with the 64% CR rate in patients reported with NOVE-HiDAC alone; 6 however, determining whether this represents a true difference would also require a larger study directly comparing the two approaches. The OS and RFS also did not appear to be substantially different than what have previously been reported for salvage therapy for either primary induction failures or relapsed patients. [6] [7] [8] [9] The correlative studies provide some insights into possible mechanisms of chemotherapy drug resistance. Akt is an important component of the PI3-kinase pathway, which is activated via c-kit signaling. 18 AML cells commonly demonstrate constitutive Akt signaling activation, 17, 24, 25 and expression is significantly increased after stimulation by SCF. 26 Enhanced Akt signaling is an important regulator of survival and chemoresistance in AML cells; 17, 25 Akt activation inhibits and side scatter (a). The blast cells were gated, and the bottom four panels are bivariate plots of pAkt versus pERK obtained from the pretreatment sample (upper panels) and at day 4 at 2 h after imatinib administration (lower panels). Baseline position in the unstimulated sample is marked with a box. As seen in the corresponding samples treated with SCF (right panels), the levels of pAkt and pERK are acutely activated relative to the unstimulated control. However, this effect is much less in the day 4 at 2 h after imatinib sample, indicating partial inhibition of c-kit.
cytarabine-induced apoptosis. 17 In contrast, ERK MAP kinase is more involved with cell proliferation rather than cell survival. 17 The current study supports the concept that Akt activation is an important mediator of AML chemotherapy resistance in vivo. There was a significant correlation between the degree of imatinib-induced pAkt inhibition and CR rate. Patients who did not achieve CR demonstrated o40% Akt inhibition with imatinib in vivo. In contrast, only 1/8 patient achieving CR demonstrated o40% Akt inhibition with imatinib. The data also suggest that patients with adverse-risk karyotypes are somewhat more likely to demonstrate lack of Akt inhibition (although this trend did not reach statistical significance), and that this may therefore be an important mechanism of drug resistance in such cases. It is not clear whether imatinib itself was important in overcoming drug resistance by inhibiting Akt expression, as overall CR rates did not appear higher than what was expected in this study, except perhaps in the cohort of relapsed patients. It is possible that imatinib-induced Akt inhibition represents a marker of chemotherapy drug sensitivity. Testing this concept Abbreviations: CR, complete response; NR, no response; NS, not significant; pAKT, phosphorylated AKT; pERK, phosphorylated ERK; SCF, stem cell factor. Sensitivity: less than 60% residual activity; resistance: less than 60% residual activity.
would require a much larger randomized trial comparing imatinib with non-imatinib-treated patients. It may also be useful to evaluable other downstream mediators of this pathway such at STAT phosphorylation; this was not evaluated in the current study. It is not clear why some cases of AML demonstrated resistance to imatinib-induced Akt inhibition. C-kit mutations are usually resistant to imatinib; however, these are rare except in corebinding factor AML, 27 and none of the 20 samples tested in patients treated at the phase II dose harbored such mutations. Variations in the degree of expression of c-kit on leukemic blasts may have influenced results. Alternatively, variations in imatinib cell uptake may be a factor. Imatinib uptake into cells is mediated via organic anion transporter-1 (OCT-1). In chronic myeloid leukemia cells, reduced OCT-1 activity is associated with impaired uptake of imatinib, 28 and has been correlated with suboptimal clinical responses to this agent. 29 We are not aware of any data evaluating OCT-1 activity in AML. Inadequate serum levels of imatinib could be another contributing factor. Dose titration curves measuring pAkt and pERK at different concentrations of imatinib in vitro, as well as pharmacokinetic studies for imatinib, has been performed in these patients and are currently being analyzed; they will be reported in a subsequent publication.
The numbers are small and this finding requires confirmation in a larger series. Nevertheless, this study suggests that Akt represents a potentially useful target for overcoming chemotherapy drug resistance in AML. Selective Akt inhibitors are currently in early clinical trials. 30 Evaluation of these agents in AML, particularly in combination with standard chemotherapy drugs, appears warranted. The flow cytometry assays performed in this study represent a useful way of evaluating the effects of such inhibitors and can be performed in real time. In future, they may potentially be useful in determining which patients may potentially benefit from such interventions. Furthermore, as the degree of inhibition with any such agents is likely to be variable, such real-time evaluation may permit individual dose titration of such agents to achieve optimal inhibition.
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